Cambridge Healthtech Institute’s Fifth Annual
Engineering ADCs
Pushing the Envelope in ADC Design with Novel Payloads, Linkers and Conjugation Chemistries
Part of the 11th Annual PEGS: the essential protein engineering summit
May 6-7, 2015 | World Trade Center | Boston, Massachusetts

Since the success of Adcetris® and Kadcyla®, there are currently more than 30 ADC compounds in clinical trials, a great testament to the attraction and promise of ADCs as therapeutics. The continued growth and success of ADCs are dependent on four factors—target antigen, antibody, payloads and linkers. The development of an effective ADC requires careful selection of the target, understanding the safety and PK profiles and optimizing the design elements of the small molecule, antibody, linkers and conjugation sites. At CHI’s Fifth Annual Engineering ADCs, our goal is to bring forth cutting-edge technologies that are continually pushing the envelope in ADC design and development.

We are now accepting proposals for oral presentation on the following topics: 

  • Novel Payloads
  • Linkers and Sites
  • Sites and Their Impact on Specificity, Stability, PK and Toxicity
  • Conjugation Chemistries
  • Target Selection, Expression and Internalization
  • Biophysical Characterization and Properties of ADCs
  • Aggregation and Hydrophobicity
  • High Throughput Screening and Generation of ADCs
  • ADC Engineering and Optimizing Delivery
  • Minimizing Off-Target Toxicities
  • Alternatives and Non-Antibody Protein Conjugates
  • ADCs for Non-Oncology Indications

Scientists who wish to present their knowledge and expertise to their colleagues are asked to click here to submit an abstract. Remember to specify the conference that you are interested in and please provide your full contact information.

The deadline for submission is October 3, 2014. 

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships. 

For more details on the conference, please contact:
Mimi Langley
Senior Conference Director
Cambridge Healthtech Institute
T: 816-472-0701

For partnering and sponsorship information, please contact:
Jason Gerardi (Companies A-K)
Manager, Business Development
Cambridge Healthtech Institute
T: 781-972-5452

Carol Dinerstein (Companies L-Z)
Director, Business Development
Cambridge Healthtech Institute
T: 781-972-5471